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cense. httpAbstract Purpose: The objective of our study was to determine the relevance of cyclins A and E
overexpression in endometrial carcinogenesis in hormone receptor-positive breast cancer patients
under tamoxifen therapy.
Experimental design: We assessed expression of cyclins A and E in Endometrial cytology samples
collected from 36 ER and PR positive breast cancer patients; under tamoxifen treatment by using
the Tao-brush non-invasive brushing cytology technique. Cyclins were detected in the collected
samples by means of immuno-cytochemistry.
The patients included in this study are a cohort of 36 breast cancer patients who were operated
upon at the National Cancer Institute – Cairo University in the period from February 2006 tomail.com (A.M. Metwally),
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194 A.M. Metwally et al.May 2008 and received tamoxifen (TAM) as part of their adjuvant treatment.
Results: Cyclins A and E were expressed in 17 and 15 of the 36 collected endometrial cytology sam-
ples (47.2% and 41.6% respectively).
Expression of cyclins A and E was highly correlated to Tamoxifen exposure duration (32 and
43 months respectively) p< 0.001. Tamoxifen median exposure duration was shortened to
21 months in cases showing positivity for either markers, while in cases showing positivity for both
cyclins, the median exposure duration was longer (44.5 months) (p< 0.001). Neither cyclin A nor E
was detected before median tamoxifen exposure duration of 11 months. Endometrial carcinoma
cases had the longest Tamoxifen exposure duration (60 months).
Conclusion: Cyclins A and E expression is involved in the carcinogenesis of endometrium in
women with breast cancer and under tamoxifen-treatment. Follow up of the patients using these
2 markers is highly recommended starting from the 12th month.
ª 2013 Production and hosting by Elsevier B.V. on behalf of National Cancer Institute, Cairo University.Figure 1 Immunostaining to cyclin E (·1000).
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Tamoxifen is the ﬁrst-choice adjuvant treatment for primary
estrogen receptor-positive (ER+) breast cancer in postmeno-
pausal women. It has been shown that survival rates in tamox-
ifen-treated women are improved as much as 50% [1].
Furthermore, tamoxifen use has also been shown to reduce
the incidence of breast cancer in healthy women at a high risk
for this disease [2–4]. The mechanism of action of tamoxifen in
breast cancer patients is that it inhibits cancer cell growth by
competitive antagonism with estrogen for its receptor [5].
One of the most signiﬁcant side effects of treatment with
tamoxifen appears to be its proliferative effect on the endome-
trium (estrogen-agonistic effect) [6]. Several studies have
evaluated the incidence of endometrial pathologies in tamoxi-
fen users, and although occurrence rates differ per study, a
higher incidence in the tamoxifen group is generally agreed
on. Endometrial pathologies associated with tamoxifen use in-
clude hyperplasia, polyps, carcinomas and sarcomas [7].
Current tools for endometrial evaluation are limited. Endo-
metrial assessments are generally based exclusively on the his-
tological appearance using eight morphologic markers
originally proposed by Noyes, Rock and Hertig [8]. However,
this classiﬁcation has been shown to have limitations, with
high inter- and intra-observer variation. Over time, incremen-
tal improvements and modiﬁcations have been performed on
this classiﬁcation on endometrial assessment. In addition to
these modiﬁcations, the use of markers has been investigated
as a way to better assess development and receptivity.
Tamoxifen induces a wave of DNA synthesis in the endo-
metrial epithelial cells. The uterine epithelial cell proliferation
is preceded by the mobilization of cyclin D1 from the cyto-
plasm to the nucleus which, together with CDK4, phosphory-
lates members of the Rb-retinoblastoma family of proteins,
pRb and p107. Subsequent to this initial nuclear accumulation
of cyclin D1, cyclin E and then cyclin A are induced that, to-
gether with the activation of CDK2, result in enhanced cyclin
E- and cyclin A-dependent CDK2 kinase activity and further
phosphorylation of pRb and p107.
Biomarkers have become of interest as potential predictors
for outcome of adjuvant tamoxifen therapy [9]. Cyclins, their
associated cyclin-dependent kinases, and cyclin-dependent
kinase inhibitory proteins play a central role in the cell cycle
progression and may also affect response to tamoxifen [9].Cyclins A and E are considered potential candidate bio-
markers in cancer [9]. Cyclin E has been shown to be the
rate-limiting activator of the mitotic G1 to S phase transition.
While over expression of cyclin-A which regulates the
S-G2-M phase transition of the cell cycle correlates closely
with clinico-pathologic parameters and prognosis in patients
with endometrial carcinoma.
The aim of the present study was to determine the role of
the cell cycle regulators cyclins A and E overexpression in
the carcinogenesis process of the endometrium in hormone
receptor-positive breast cancer patients under tamoxifen ther-
apy Figure 1–5.
Patients
The patients included in this study are a cohort of 36 breast
cancer patients who were operated at the national cancer insti-
tute – Cairo University in the period from February 2006 to
May 2008. Out of the 36 patients, 12 refused to participate
in the study and 4 cases were excluded as their samples were
inadequate.
Inclusion criteria:.
1- Histologically diagnosed breast cancer cases had an
estrogen and progesterone hormonal receptor positive
proﬁle as a must positive inclusion criterion.
Figure 2 Immunostaining to cyclin A (·400).
Figure 3 Atypical glandular cells of undetermined signiﬁcance
(AGUS).
Figure 4 Atypical endometrial cells suggestive of
adenocarcinoma.
Figure 5 High power view of cells suggestive of
adenocarcinoma.
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and/or chemotherapy and were kept under Tamoxifen
treatment at a dose of 20 mg/day up to 5 years according
to their treatment protocol.
Our selected group of patients were exposed to Tamoxifen
at different periods ranging from 5 to 60 months at the time of
sampling retrieval.
Complete medical history and physical examination work-
up were done before enrolling patients in this study.
1- Complete blood picture.
2- Blood chemistry, urea, creatinine, uric acid, bilirubin,
SGOT, SGPT, Alkaline phosphatase, total protein, albumin,
PT, PTT, Na, K
3- Chest X-ray, bone scan, abdominal sonar, CT scan and
echocardiography when indicated.
4- Conﬁrming the ER and PR by immunohistochemical
staining (only positive estrogen and progesterone receptor
patients were included).
History included also, revision of all prognostic factors at
the time of diagnosis including: tumor size, grade, histological
type, and lymph node involvement, type of treatment they re-
ceived (surgery, post-operative radiotherapy or adjuvant
chemotherapy).Methods
Endometrial cytology using the endometrial cytology
Tao- brush non-invasive technique was used for discovering
and diagnosing malignant and premalignant states of the
endometrium according to the criteria described by DeMay
[10].
Endometrial cytology samples were collected from the se-
lected 36 breast cancer patients; by using the endometrial
cytology Tao- brush non-invasive technique. The recovered
cytology samples were subjected to immunocytochemistry
study using antibodies against cyclin A and cyclin E. All
immunocytochemistry results were correlated with the routine
cytology using the PAP stain.
The immunochemistry method for staining the recovered
cytology sample with the biomarker cyclins A and E: The eth-
anol–ﬁxed cytology slides were stained using the Imuno-cyto-
chemical staining; performed using the DAKO LSAB kit
(Labeled streptavidin Biotin) with mouse anti human cyclin
A and mouse anti human cyclin E.
Table 2 Relation of the cytological type and cyclin immuno-
reactivity of the endometrial samples to tamoxifen exposure
duration in the 36 breast cancer patients.
Results Number Median TAM.
Duration/month
Range p Value
Cytological Type
AGUS 11 18(5–51) 46
Reactive Inﬂammatory 12 17(5–52) 47 0.09
changes Atrophy 10 15.5(7–45) 38
Cyclin A
+ve 17 32(11–60) 49
ve 19 12(15–41) 36 <0.001
Cyclin E
+ve 15 43(18–60) 42
ve 21 12(5–41) 36 <0.001
Cyclins A and E
Both +ve 12 44,5 (18–60) 42
Either +ve 8 21(11–25) 14 <0.001
Both ve 16 11 (5–41) 36
Total 36
196 A.M. Metwally et al.Immunocytochemistry was done and evaluated at the Na-
tional cancer Institute –Cairo University by means of a stan-
dard protocol.
All immunochemical staining included positive and nega-
tive control.
Statistical methods
SPSS version 12.0 (Chi IL, USA) was used for data manage-
ment and analysis. Median and range described quantitative
data. Mann–Whitney U test compared means of 2 independent
groups and Kruskal Wallis test compared more than 2 inde-
pendent groups. All tests were two-sided. P-values 60.05 were
considered signiﬁcant.
Results
The mean age at diagnosis was 45.4 (±7.73) mostly post-men-
opause (ranging between 43 and 65 years).
Breast cancer patients subjected to surgery were mostly of
the aggressive and invasive form.
The mean tumor size- diameter was approximately 4.5 cm
(±2.3). The relative frequency of their histological types
showed invasive duct carcinoma to be 80.6% (29/36) of all
studied patients, (11.1%) 4/36 were lobular + duct carcinoma
while mucinous carcinoma were 3/36 (8.4%).
Axillary lymph node dissection showed metastasis in 21/36
(58.3%). The TNM staging showed predominance of stage II
58.3% 21/36 cases, followed by the GIII 25%, 9/36 and 6/36
samples (16.7%) were GI.
Smears showed cytological criteria as follows: Atypical
Glandular cells of undetermined signiﬁcance (AGUS) 11/36
(30.6%), Atrophy 10/36 (27.7%.).Reactive inﬂammatory
changes 12/36 (33.3%). One case had atypical precancerous
changes (2.8%) and 2 cases had endometrial carcinoma
(5.6%). (Table 1).
Immuno-reactivity of the collected endometrial samples to
Cyclin-A: showed 47.2% (17/36) positivity for cyclin A. How-
ever, 15 out of 36 cases were immune reactive for cyclin E
(Table 1).Table 1 Cytological results and cyclin immune-reactivity of
the collected endometrial samples of the 36 breast cancer
patients.
Results Number Percent
Cytological type
AGUS 11 30.6
Atrophy 10 27.7
Reactive inﬂammatory changes 12 33.3
Atypical precancerous changes 1 2.8
Endometrial carcinoma 2 5.6
Cyclin A
+ve 17 47.2
ve 19 52.8
Cyclin E
+ve 15 41.7
ve 21 58.3
Total 36 100%For the endometrial cytology results, there is an inclination
toward increased degree of severity with the increase in the
time of exposure to TAM (p= 0.09) (Table 2). The Tamoxifen
exposure duration for the endocervical cancer and atypia cases
is 60 months.
A high signiﬁcance was noticed between cyclins A and E
positive samples and a longer Tamoxifen exposure duration/
month (32 and 43 months respectively). The median Tamoxi-
fen exposure duration for cases showing positivity for either
A or E is 21 months, while for cases showing positivity for cyc-
lins A and E, the median TAM exposure duration is
44.5 months. (p< 0.001) (Table 2).
According to Table 2 neither cyclin A nor E was detected
before a median of 11 months.
Discussion
In 1989 Fornander provided early evidence that tamoxifen is a
causal agent in the development of endometrial cancer, a 6.4-
fold increase in the relative risk of developing endometrial can-
cer in a group of postmenopausal women with early breast
cancer that was treated with adjuvant tamoxifen. The greatest
risk occurred after ﬁve years in women who received 40 mg per
day of tamoxifen [11]. Fisher in 1994 conﬁrmed these ﬁndings
when he reported the results of the National Surgical Adjuvant
Breast and Bowel Project B-14 trial [12]. In 2009 Qureshi stud-
ied the incidence and type of endometrial abnormalities in
long-term users of tamoxifen with breast cancer. [13].
Previously mentioned papers are in support to our present
work, for endometrial cytology and this suggests an associa-
tion between tamoxifen therapy and evidence of endometrial
pathology of possible neoplastic potential.
Bland et al. studied 732 women with endometrial carci-
noma, 59 patients (8%) had a previous diagnosis of breast can-
cer, of whom 29 (49%) had used tamoxifen. He also found that
tamoxifen use for at least 60 months is associated with high
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fen use [14].
Further researches on a bigger sample of patients in Egypt
are recommended to analyze the precise percentage of endome-
trial carcinoma in the general patient population versus those
receiving TAM adjuvant therapy and the difference between
their histo-pathological types.
Comparing the severity of endometrial changes in relation
to tamoxifen exposure duration, we found an inclination to-
ward increased degree of severity with the increase in TAM
exposure duration. The endocervical cancer samples had the
longest tamoxifen exposure duration (60 months) followed
by the AGUS and active inﬂammation cases (18 and
17 months respectively) then, atrophy (15.5 months).
Previous studies showed that the risk of developing endo-
metrial cancer is dose and time dependent [15]. Also, Bergman
et al. explained that long term tamoxifen users had a worse
prognosis of endometrial cancers, which seems to be due to less
favorable histology and higher stage; this was conﬁrmed by
Prat, Jaime [16,17]. The same results were found by LE Donne
where he found a signiﬁcant correlation between the duration
of TAM treatment and the severity of endometrial pathology.
[18].
Our present study coincides and adds to previous existing
data, suggesting a relationship between tamoxifen duration
of use and development of endometrial carcinoma of more
aggressive histologic types.
Progression through G1-S transition and S phase of the cell
cycle is mediated by cyclin-dependent kinase 2 (cdk2), which
interacts with several cyclins. Two of these; cyclin E and cyclin
A, are over expressed in many cancers. Expression and prog-
nostic role of these cyclins in solid tumors is unknown [19].
In this study, we have analyzed the immune reactivity and
prognostic relevance of the recently discovered cdk2-interact-
ing cyclins A and E in the endometrium of estrogen recep-
tor-positive (ER+) breast cancer patients receiving TAM
adjuvant treatment.
Various methods are available for the measurement of pro-
liferation rates in tumors, including mitotic counts, estimation
of the fraction of cells in the S–phase of the cell cycle and
immuno-histochemistry of proliferation-associated antigens.
Proliferation rate can provide useful information on prognosis
and aggressiveness of individual cancers and can be used to
guide treatment in clinical practice.
Tsuda et al. studied the expression of cyclin D1, cyclin
D2 and cyclin D3 in 10 normal endometrium, 18 endome-
trial hyperplasia and 35 endometrial carcinoma samples.
There was no expression of the D1, D2 or D3 in both nor-
mal proliferative and hyper plastic samples while cancer
cases had 28.6% D1 and 2.9% D2 nuclear localization
and no expression (0%) of D3 [20]. Recent studies indicated
that molecular markers are sensitive in the detection of the
early changes in the carcinogenesis of the endometrium
where there are many molecular abnormalities that are asso-
ciated with the transformation of endometrium following
tamoxifen administration [19]. Miranda et al. found that
the use of TAM in postmenopausal women might be associ-
ated with an increased cellular proliferation in endometrial
polyps without interfering angiogenesis or inactivation of tu-
mor suppressor proteins.[21].
In the present study, a non-invasive method was employed
to study the expression status of cyclin A and cyclin E thatmay inﬂuence the cell cycle mechanism and thus malignant po-
tential. We studied the value of Cyclins A and E as biomarkers
for determining the endometrial changes as a result of tamox-
ifen administration that may lead to malignancy.
Horre´e et al. mentioned that cyclins A and E are expressed
during the carcinogenesis of the endometrium and showed that
expression of cyclin A and Ki67 gradually increased from nor-
mal through hyperplasia to carcinoma indicating their poten-
tial importance in both early and late carcinogenesis. Also he
showed that cyclin E and P53 increased from hyperplasia to
carcinoma underlining their role in late carcinogenesis [22].
Our data showed Immunoreactivity of the collected endo-
metrial samples to both Cyclin-A (47.2%), and cyclin E
(41.6%). Samples were immune reactive to A and/or E at dif-
ferent percentages depending on the cytological type of the
endometrial change. The greatest percentage appeared in both
endometrial carcinoma and atypia cases where they were
100% immunoreactive to A and E. Accordingly, cyclins A
and E are expressed in precancerous and cancer cases which
means that Cyclins A and E are expressed during the carcino-
genesis of the endometrium as a result of tamoxifen
administration.
A and E levels increase proportionate to duration of tamox-
ifen exposure. There was a highly signiﬁcant correlation
(p< 0.001) between cyclins A and E positivity and a longer
Tamoxifen exposure duration. Neither cyclin A nor E was
detected before a median time of 11 months.
We also found that tamoxifen exposure duration in cases
showing positivity for both markers was signiﬁcantly higher
(44.5 months) than the duration in cases showing positivity
for either cyclin A or E (21 month) .
Accordingly, the presence of both cyclins A and E together
have a cumulative effect and emphasizes the possibility of
malignant transformation. So follow up of cyclins positive
cases at an earlier time is highly recommended, as the cyclin
expression for these cases could be considered as a marker
for the transformation.
It is very important to study when the cyclin over expres-
sion occurs within the cytological groups. For the AGUS
group we found that the median time for cyclins A and E over
expression was 20 and 35.5 months respectively. For the active
inﬂammation it was 30 months for both A and E. For atrophy,
it was 44 months for A and 43.5 for E.
These results might give us some information about the car-
cinogenesis process in the endometrium where AGUS type is
formed after 18 months from tamoxifen administration; in
some cases of the AGUS group, cyclin A is over expressed
after 20 months while cyclin E is overexpressed after
35.5 months respectively. For the active inﬂammation type, it
is formed after 17 months from tamoxifen administration, in
some cases of this group cyclins A and E are over expressed
after 30 months. The atrophy group is formed after
15.5 months from TAM administration, some cases of this
group over express cyclins A and E after 44 and 43.5 months
respectively. Finally malignant transformation occurs after
5 years.
So we can conclude that the cytological changes of the
endometrium should be supported by over expression of
cyclins A and E where their overexpression enforces the cells
to go toward malignancy.
The routine use of endometrial biopsy of asymptomatic
tamoxifen users failed to identify occult cancers [7].
198 A.M. Metwally et al.Love et al. performed transvaginal ultrasounds on 357
asymptomatic patients with breast cancer who received tamox-
ifen. No signiﬁcant lesions were detected in any of the women
[23].
In this paper we studied the endometrial cytology using the
Tao- brush non-invasive technique for discovering and diag-
nosing malignant and premalignant states of the endometrium
according to the criteria described by DeMay [10].
Our results provide preliminary data to suggest that the
immunocytology study of cyclins A and E may provide an ini-
tial surveillance tool in hormone receptor-positive breast can-
cer patients who were treated with tamoxifen based therapy.
This method could provide increased sensitivity and speciﬁcity
with reduced procedural risk and signiﬁcant cost savings to the
health care system.
Conclusion
Cyclins A and E expression is involved in the carcinogenesis of
endometrium. The over expression of the cell cycle regulators
(cyclins A and E) in the endometrial cells seems to appear after
11 months from the tamoxifen exposure. So follow up of the
patients using these 2 markers is highly recommended starting
from the 12th month. A special attention for cyclin positive
cases is clearly needed, where the cyclin over expression in
these cases may be an indicator for their transformation. For
malignant transformation of the endometrium, the cytological
changes should be supported by over expression of cyclins A
and E where their overexpression enforces the cells to go
toward malignancy.
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